Imfinzi
55,000 Per 30
Durvalumab[1] (trade name imfinzi) is an fda-approved immunotherapy for cancer, developed by medimmune/astrazeneca.[2] it is a human immunoglobulin g1 kappa (igg1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (pd-l1) with the pd-1 (cd279). Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
